Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval ...
Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback